ANGO

Business Context and Reporting Period

Company: AngioDynamics, Inc.
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended May 28, 2005 (52 weeks)
Business Overview: AngioDynamics designs, develops, manufactures, and markets innovative medical devices for minimally invasive, image-guided procedures to treat peripheral vascular disease (PVD). The company focuses on interventional radiologists and vascular surgeons. Key product lines include angiographic catheters, hemodialysis catheters, VenaCure laser systems, and image-guided vascular access products.
Recent Corporate Events: The company completed its Initial Public Offering (IPO) in May 2004 and was spun off from its former parent, E-Z-EM, Inc., via a tax-free distribution in October 2004.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 22.9% to $60.3 million, driven by new product introductions (specifically in image-guided vascular access and hemodialysis catheters) and an expanded domestic sales force.
• Margin Expansion: Gross margin improved to 55.4% from 52.6%, attributed to increased sales volume, favorable product mix, and improved manufacturing efficiencies.
• Expense Increases: Operating expenses rose to $25.7 million (from $20.7 million). Sales and marketing expenses increased 18.0% due to hiring six new sales representatives. General and administrative expenses rose 42.5% primarily due to professional fees associated with becoming a public company.
• Debt Reduction: Total debt decreased significantly as the company repaid $3.0 million in notes payable to its former parent, E-Z-EM, using IPO proceeds. Remaining debt consists of industrial revenue bonds for facility expansion.
• Liquidity: Cash and cash equivalents surged to $14.5 million, bolstered by IPO proceeds and strong operating cash flows ($4.8 million).

Guidance, Outlook, Risks, and Contingencies

• Outlook: Management expects R&D expenditures to reach approximately 8% of net sales by the end of fiscal 2006. The company intends to grow through selective acquisitions but notes that cash resources are limited and additional financing may be required.
• Restrictions: Due to the tax-free spin-off from E-Z-EM, the company is restricted from issuing more than approximately 5.5 million shares of common stock in capital raising transactions for two years following the distribution.
• Legal Proceedings:
  • Diomed, Inc. v. AngioDynamics: Diomed alleges patent infringement regarding VenaCure laser products. A recent court ruling (Markman ruling) favored AngioDynamics on claim construction. AngioDynamics is indemnified by its supplier, biolitec.
  • Product Liability: Two lawsuits allege defective catheters caused patient deaths. One was settled by supplier Medcomp for $500,000; the other is being defended by Medcomp under an indemnification agreement.
• Key Risks:
  • Supplier Concentration: Approximately 43% of revenues are derived from products manufactured by third parties. Medcomp supplies all hemodialysis catheters (26% of sales), and biolitec supplies VenaCure lasers (13% of sales).
  • Competition: Intense competition from larger firms (e.g., Boston Scientific, Cook) with greater resources.
  • Reimbursement: Dependence on third-party payors (Medicare, private insurers) for coverage of procedures using AngioDynamics products.